JMP Securities raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $75 from $64 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree
- Rhythm Pharmaceuticals announces five presentations at ESPE 2024
- Rhythm announces publication of setmelanotide Phase 3 results in The Lancet
- Rhythm Pharmaceuticals price target raised to $80 from $53 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $69 from $64 at H.C. Wainwright